流感病毒及新型冠状病毒相关侵袭性肺曲霉病的诊治进展

Progress in diagnosis and treatment of influenza-associated pulmonary aspergillosis and COVID-19-associated pulmonary aspergillosis

摘要: 流感病毒相关侵袭性肺曲霉病(influenza-associated pulmonary aspergillosis，IAPA)和新型冠状病毒相关侵袭性肺曲霉病(COVID-19-associated pulmonary aspergillosis，CAPA)均为重症病毒性肺炎并发侵袭性肺曲霉病(invasive pulmonary aspergillosis，IPA)，在重症患者中发病率和病死率均较高。肺组织活检仍是诊断IAPA和CAPA的金标准，而传统生物标志物检测的诊断价值有限，需要新型诊断方法辅助临床诊断。在对IAPA和CAPA患者的抗真菌治疗中应关注药物相互作用和耐药性情况，预防真菌感染的研究和新型抗真菌药物的研究正在进行中。

Abstract: Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA) are severe viral pneumonia complicated by invasive pulmonary aspergillosis (IPA), caused high morbidity and mortality in critically ill patients. Lung biopsy is still the gold standard for the diagnosis of IAPA and CAPA, while traditional biomarker testing has limited diagnostic value and requires novel diagnostic methods to assist clinical diagnosis. Drug interactions and resistance should be concerned in antifungal therapy for patients with IAPA and CAPA, and researches in preventing fungal infections and novel antifungal drugs are ongoing.